U.S. Patent Office Allows EP4 Receptor Antagonist Use Patent for Immuno-oncology Therapy

On April 7, 2021 AskAt Inc. reported that it received a notice of allowance from the U.S. Patent Office of a use patent for its EP4 receptor antagonist in immuno-oncology therapy (Appl. No. 16/385,524) (Press release, AskAt, APR 7, 2021, View Source [SID1234577623]). AskAt and Arrys Therapeutics, a wholly owned subsidiary of Ikena Oncology ((NASDAQ: IKNA) headquartered in Boston, Massachusetts), jointly filed the patent application. The patent will remain effective until April 15, 2039.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!